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ORIGINAL RESEARCH
Cardiospecific Overexpression of ATPGD1 
(Carnosine Synthase) Increases Histidine 
Dipeptide Levels and Prevents Myocardial 
Ischemia Reperfusion Injury
Jingjing Zhao, PhD; Daniel J. Conklin, PhD; Yiru Guo, PhD; Xiang Zhang, PhD; Detlef Obal, MD, PhD;  
Luping Guo, MD; Ganapathy Jagatheesan, PhD; Kartik Katragadda, MD; Liqing He, PhD; Xinmin Yin, MS;  
Md Aminul Islam Prodhan, PhD; Jasmit Shah, PhD; David Hoetker, MS; Amit Kumar, PhD; Vijay Kumar, PhD; 
Michael F. Wempe, PhD; Aruni Bhatnagar, PhD; Shahid P. Baba, PhD
BACKGROUND: Myocardial ischemia reperfusion (I/R) injury is associated with complex pathophysiological changes charac-
terized by pH imbalance, the accumulation of lipid peroxidation products acrolein and 4- hydroxy trans- 2- nonenal, and the 
depletion of ATP levels. Cardioprotective interventions, designed to address individual mediators of I/R injury, have shown 
limited efficacy. The recently identified enzyme ATPGD1 (Carnosine Synthase), which synthesizes histidyl dipeptides such 
as carnosine, has the potential to counteract multiple effectors of I/R injury by buffering intracellular pH and quenching lipid 
peroxidation products and may protect against I/R injury. 
METHODS AND RESULTS: We report here that β- alanine and carnosine feeding enhanced myocardial carnosine levels and pro-
tected the heart against I/R injury. Cardiospecific overexpression of ATPGD1 increased myocardial histidyl dipeptides levels 
and protected the heart from I/R injury. Isolated cardiac myocytes from ATPGD1- transgenic hearts were protected against 
hypoxia reoxygenation injury. The overexpression of ATPGD1 prevented the accumulation of acrolein and 4- hydroxy trans- 2- 
nonenal–protein adducts in ischemic hearts and delayed acrolein or 4- hydroxy trans- 2- nonenal–induced hypercontracture in 
isolated cardiac myocytes. Changes in the levels of ATP, high- energy phosphates, intracellular pH, and glycolysis during low- 
flow ischemia in the wild- type mice hearts were attenuated in the ATPGD1- transgenic hearts. Two natural dipeptide analogs 
(anserine and balenine) that can either quench aldehydes or buffer intracellular pH, but not both, failed to protect against I/R 
injury. 
CONCLUSIONS: Either exogenous administration or enhanced endogenous formation of histidyl dipeptides prevents I/R injury by 
attenuating changes in intracellular pH and preventing the accumulation of lipid peroxidation derived aldehydes.
Key Words:  acrolein ■  anserine ■ balenine ■ carnosine ■ carnosine synthase ■ intracellular pH ■ ischemia reperfusion
Myocardial ischemia leads to a complex series of pathological changes that involve multiple deleterious events such as a switch to an-
aerobic glucose metabolism and intracellular acidi-
fication and increased generation of reactive oxygen 
species (ROS), which initiate the formation of toxic 
lipid peroxidation products. If uninterrupted, these 
changes lead to extensive tissue injury and sustained 
contractile dysfunction. Therefore, the most effective 
intervention to rescue ischemic myocardium is timely 
reperfusion using thrombolytic therapy or by percuta-
neous coronary intervention. However, reperfusion by 
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itself initiates a second cascade of complex patholog-
ical events, collectively defined as “reperfusion injury,” 
characterized by rapid restoration of intracellular pH 
([pH]i), release of cardiac enzymes, mitochondrial per-
meability transition pore opening, and eventually cell 
death.1 In the past, most therapeutic interventions to 
limit ischemia reperfusion (I/R) injury were designed to 
target a single effector (eg, antioxidants, pH buffers, 
or metabolic substrates),which showed only limited ef-
ficacy because preventing one aspect of I/R did not 
necessarily attenuate injury attributed to other contrib-
uting processes.
Multifunctional histidyl dipeptides, such as car-
nosine (β- alanine- histidine), have been evolution-
arily conserved for at least 530  million years and 
are present in the muscles of families as distantly 
related as fish, amphibians, birds, and mammals.2 
Although the specific roles of these peptides in mus-
cle physiology is still unclear, it is thought that by 
the virtue of their dissociation constant (pKa) value, 
which is close to physiological pH (7.01), some of 
these peptides may buffer [pH]i.
3 This property 
may be particularly useful under conditions of hy-
poxia, when high amounts of protons are gener-
ated by anaerobic glycolysis. However, in addition 
to buffering, these peptides can also quench ROS 
as well as reactive aldehydes such as acrolein, 
and 4- hydroxy- trans- 2- nonenal (HNE),4–6 produced 
during the oxidation of membrane lipids. It has also 
been proposed that histidyl dipeptides act as a 
neuromodulators or a neurotransmitters.7 In most 
vertebrates, histidyl dipeptides are present in high 
concentrations in skeletal muscle (1–10 mmol/L) and 
heart (0.1–1 mmol/L) tissues,2 in which they are lo-
cally synthesized by the enzyme ATPGD1 (carnosine 
synthase) from their precursors β- alanine and histi-
dine.8 Although the chemical properties of histidyl 
dipeptides are well suited to limit the effects of tissue 
hypoxia and I/R injury, it is unclear whether increas-
ing the endogenous synthesis of these peptides by 
ATPGD1 overexpression protects against tissue in-
jury and whether the complex I/R pathophysiology 
is affected by augmenting histidyl dipeptide levels.
During myocardial ischemia, the most prompt 
and marked change that occurs within the seconds 
after the onset of ischemia is cellular acidosis.9,10 
This decrease in [pH]i causes a rapid breakdown of 
high- energy phosphates, increases inorganic phos-
phates, and downregulates contraction near the 
ischemic zone.9,11 In response to ischemic acido-
sis, H+ ions are extruded by the Na+- H+ exchanger 
to normalize [pH]i during reperfusion, but this results 
in intracellular accumulation of Na+, which in turn is 
exchanged for Ca2+ overload and the opening of the 
mitochondrial permeability pore.12,13 Several Na+- H+ 
exchanger inhibitors in animal models had either 
resulted in modest recovery or had significant det-
rimental effects on I/R injury, but the clinical trials 
involving Na+- H+ exchanger inhibitors were largely 
negative.14,15 In addition to acidosis, I/R generates 
toxic lipid peroxidation products, which accumulate 
in the heart even after reperfusion.16,17 These prod-
ucts, particularly HNE and acrolein, can lead to cor-
onary vasodilation18 and decrease systolic pressure19 
and arrhythmias.20,21 They can also deplete ATP lev-
els, alter Na+ and K+ conductances, and induce cell 
death.20 The contribution of these aldehydes to I/R 
injury is supported by extensive evidence showing 
that the deletion of enzymes that detoxify these al-
dehydes, including glutathione- S- transferase P,22 
aldose reductase,23,24 and aldehyde dehydrogenase 
2, increases I/R injury.25,26 Therefore, a combinatorial 
strategy that could reduce acidification and prevent 
the accumulation of reactive aldehydes might be well 
suited to ameliorate concurrently several adverse 
factors of I/R injury.
CLINICAL PERSPECTIVE
What Is New?
• This research demonstrates that enhancing 
myocardial production of histidyl dipeptides 
by cardiospecific carnosine synthase overex-
pression or feeding carnosine and β-alanine 
imparts protection from ischemia reperfusion 
injury.
• Decrease in intracellular pH and the accumu-
lation of reactive aldehydes are 2 deleterious 
characteristics of ischemia reperfusion injury.
• Histidyl dipeptides by their dual ability to buffer 
intracellular pH and scavenging reactive alde-
hydes impart protection from ischemia reperfu-
sion injury.
What Are the Clinical Implications?
• Histidyl dipeptides are food components found 
in red meat that are increased by exercise.
• Therefore, our findings lay the foundation to test 
the translational feasibility of these dipeptides 
as a prophylactic measure to prevent ischemic 
heart diseases.
Nonstandard Abbreviations and Acronyms
AAR  area at risk
ATPGD1 carnosine synthase
I/R  ischemia reperfusion
LFI  low-flow ischemia
ROS  reactive oxygen species
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Previous work from our laboratory and others 
have shown that the perfusion of isolated murine 
hearts by carnosine offers modest protection against 
I/R injury,27,28 and intravenous injection of carnosine 
in rats imparts cerebroprotection.29 Nevertheless, 
from these studies it is not clear whether these di-
peptides act at intracellular sites or if these effects 
are systemic. Importantly, it is not known whether the 
cardioprotective effects of carnosine are related to 
pH buffering and/or aldehyde quenching and how it 
affects glucose use in the heart. In addition, in hu-
mans, histidyl dipeptides are rapidly hydrolyzed by 
the carnosine- specific peptidase carnosinase pres-
ent in the serum, which limits its bioavailability.30 
Recent clinical trials in heart failure patients showed 
that carnosine feeding did not improve cardiac func-
tion, reflecting a limitation to carnosine ingestion in 
this setting.31 Hence, we increased the myocardial 
histidyl dipeptide pool by the cardiospecific over-
expression of ATPGD1. Our results showed that 
ATPGD1 overexpression enhances the myocardial 
pool of histidyl dipeptides and diminished myocar-
dial infarct size. The results of mechanistic studies 
showed that both aldehyde quenching and [pH]i buff-
ering are essential actions for optimal cardio protec-
tion by histidyl dipeptides.
METHODS
Adult male C57BL/6 mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME). All animal proto-
cols were reviewed and approved by the University of 
Louisville Institutional Animal Use and Care Committee. 
Detailed methodology is described in Data S1. 
ATPGD1- transgenic (Tg) mice were generated using 
the α–myosin heavy chain promoter and subjected 
to in vivo coronary ligation and reperfusion to induce 
I/R injury. Nuclear magnetic resonance (NMR) was 
used to quantify changes in pH in isolated perfused 
hearts, and metabolites were measured by liquid chro-
matography–mass spectrometry or gas chromatog-
raphy–tandem mass spectrometry (see Data S1, and 
raw data will be provided on request). All of the data 
and methods used in the analysis and material used 
to conduct research will be made available at request. 
Statistical Analysis
The levels of carnosine and infarct size in carnosine and 
β- alanine–treated and untreated mice hearts, infarct 
size of C57BL/6, wild type littermates (WT mice) and 
ATPGD1- Tg mice hearts subjected to in vivo ischemia 
reperfusion, and postischemic functional recovery fol-
lowing global ischemia in WT and ATPGD1- Tg–isolated 
mice hearts were analyzed by using unpaired t test. 
High- energy phosphates measured by 31P NMR and 
13C lactate formation generated during low- flow is-
chemia (LFI) and reperfusion in WT and ATPGD1- Tg 
mice hearts were analyzed using repeated analysis 
of variance. Synthesis of carnosine in hearts isolated 
from WT and ATPGD1- Tg mice were analyzed by using 
the Mann- Whitney nonparametric test. Cytotoxicity 
of isolated cardiomyocytes isolated from WT and 
ATPGD1- Tg mice hearts that were subjected to nor-
moxia and hypoxia/reperfusion and generation of al-
dehyde protein adducts after ischemia in the WT and 
ATPGD1- Tg mice hearts were analyzed by using 2- way 
analysis of variance followed by bonferroni test. To 
estimate the survival time of isolated cardiomyocytes 
between different treatments, 4 different models of es-
timating survival were evaluated as mentioned previ-
ously.32 Fits of exponential, Weibull, linear exponential, 
and γ distribution to the data were estimated using a 
regression method for survival distribution fitting.33 The 
best fits were obtained for the Weibull distribution. This 
distribution has been used to determine the survival 
in continuous carcinogenesis and isolated cardiomyo-
cytes.22,32,34 Survival data for cardiac myocytes were 
modeled using the Weibull survival distribution. Curve 
fitting was performed using the Proc NLIN procedure 
in SAS version 9.4 software (SAS Institute, Inc., Cary, 
NC). Two Weibull distributions were compared as de-
scribed previously.35 The number of observations “n” 
refers to the number of different mice hearts, and ~100 
cells were counted from each mouse heart. Statistical 
significance was accepted at P<0.05. Group data are 
mean±SD and mean±SEM.
RESULTS
Carnosine and β- Alanine Feeding Protect 
the Heart From I/R Injury
To increase intracellular levels of carnosine, we 
placed adult  male C57BL/6 mice on drinking water 
containing β- alanine (20  mg/mL). β- alanine is the 
nonproteinogenic rate- limiting amino acid that is 
used for carnosine synthesis. It is widely used as 
a food supplement to increase carnosine levels in 
skeletal muscle.36,37 As shown in Figure  1A, after 
7 days on β- alanine–containing water, carnosine lev-
els were ≈7- fold higher in the hearts of treated than 
untreated mice (0.31±0.05 nmoles/mg protein versus 
2.26±0.08 nmoles/mg protein). There was no change 
in anserine levels (0.0754±0.008 nmoles/mg protein 
versus 0.068±0.001 nmoles/mg protein; Figure S1E). 
To evaluate the effect of elevated myocardial carno-
sine levels, these mice were subjected to coronary 
ligation for 30 minutes followed by 24 hours of rep-
erfusion. Heart tissues were perfused with Evans 
blue dye and stained with 2,3,5- triphenyl tetrazo-
lium chloride to characterize the area at risk (AAR) 
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and infarct size. Figure 1B shows the representative 
2,3,5- triphenyl tetrazolium chloride micrographs of 
the heart tissues. Quantitative analysis of Evans blue 
dye and 2,3,5- triphenyl tetrazolium chloride stain-
ing, indicated that the AAR/left ventricle ratio was 
similar between the untreated and β- alanine–treated 
mice (Figure  1C).  However, the infarct area as a 
ratio of AAR was significantly lower in the β- alanine–
treated than in the untreated mice (Figure  1D). To 
examine whether carnosine itself was as effective 
as its precursor, we placed the WT mice on drink-
ing water ±10  mg/mL carnosine for 7  days, which 
led to a 5- fold increase in myocardial carnosine lev-
els (0.15±0.04 nmoles/mg protein versus 0.71±0.19 
nmoles/mg protein; Figure 1E). Again, there was no 
change in anserine levels (Figure S1F). Similar to β- 
alanine, carnosine feeding protected the heart from 
I/R damage, as reflected by a lower infarct area/AAR 
ratio in the hearts of the carnosine- fed mice sub-
jected to coronary ligation and perfusion (Figure 1H). 
Taken together, these results suggest that increasing 
myocardial levels of carnosine via the delivery of car-
nosine or its precursor has an infarct- sparing effect. 
In addition, these findings strengthened the ration-
ale for testing the role of ATPGD1, which synthesizes 
these dipeptides.8
Cardiospecific Overexpression of ATPGD1 
Protects Against I/R Injury
The enzyme ATPGD1 ligates β- alanine and histidine to 
form carnosine, which could be further methylated by 
carnosine N- methyltransferase to form anserine.2,8,38 To 
examine whether the cardiospecific ATPGD1 overexpres-
sion increases myocardial levels of histidyl dipeptides, 
we generated the Tg mice overexpressing the mouse 
ATPGD1 gene under the control of α–myosin heavy chain 
promoter on a C57/BL6 background. Western blot analy-
sis confirmed that the ATPGD1 expression in the heart was 
increased ≈20- to 25- fold compared with the littermate 
non- Tg control (WT) mice (Figure 2A). Liquid chromatog-
raphy–mass spectrometry measurements showed that 
Figure 1. β- alanine and carnosine feeding protect against ischemia reperfusion injury. 
A. Wild- type C57BL/6 mice were provided drinking water without (n=4) or with β- alanine (20 mg/mL; n=3) for 7 days. Myocardial 
carnosine levels were measured by ultra- performance liquid chromatography/tandem mass spectrometry. Inset is a representative 
chromatogram of carnosine and internal standard (IS) tyrosine histidine. B, Hearts of untreated and β- alanine–fed mice subjected 
to 30 minutes of ischemia followed by 24 hours of reperfusion. Representative cross- sections of 2,3,5 triphenyltetrazolium chloride 
staining shows the infarct zone depicted by a white area, the red area is the area at risk (AAR), and the blue region is the remote 
zone. (Scale bar=1 mm.) C and D, The relative ratios of the AAR to the left ventricle (LV) area and the infarct area (IF) to the AAR 
were compared between the untreated (n=8) and β- alanine–fed (n=9) fed mice. E, Mice provided drinking water with or without 
carnosine (10 mg/mL) for 7 days; n=3 mice in each group. F, Representative cross- sections of the untreated and carnosine- treated 
mice subjected to 30 minutes of ischemia followed by 24 hours of reperfusion. G and H, Relative ratio of AAR to the LV area and IF to 
the AAR were compared between the untreated (n=9) and carnosine- treated mice groups (n=11). *P<0.05 vs the untreated mice group. 
A
E
B
F
C D
G H
D
ow
nloaded from
 http://ahajournals.org by on January 10, 2021
J Am Heart Assoc. 2020;9:e015222. DOI: 10.1161/JAHA.119.015222 5
Zhao et al Carnosine Protects From Ischemia Reperfusion
the carnosine and anserine levels were increased 30- to 
40- fold and 10- to 12- fold, respectively, in the ATPGD1- Tg 
compared with the WT hearts (carnosine, WT: 0.31±0.04 
nmoles/mg protein versus ATPGD1Tg: 14.57±0.39 
nmoles/mg protein; anserine, WT: 0.075±0.008 nmoles/
mg protein versus ATPGD1 Tg: 0.791±0.137 nmoles/mg 
protein; Figure  2B, Figure S1A and S1B). The levels of 
both of these dipeptides in gastrocnemius skeletal mus-
cle remained unchanged, attesting to the fidelity of the 
α–myosin heavy chain promoter (Figure S1C and S1D). 
Figure  2. Cardiospecific overexpression of ATPGD1 (carnosine synthase) increases histidyl 
dipeptide levels and protects against ischemia reperfusion injury.
A, Representative Western blot of ATPGD1 in wild- type (WT) and ATPGD1- transgenic (Tg) hearts (i); lower 
panel represents the band intensity normalized to tubulin between the 2 groups (ii); n=4 in each group. 
B, Fold changes in carnosine and anserine levels in WT and ATPGD1- Tg hearts, n=4 in each group. C, 
Representative images of 2,3,5- triphenyl tetrazolium chloride–stained WT and ATPGD1- Tg hearts after 
30 minutes of ischemia followed by 24 hours of reperfusion. D and E, Quantification of the ratio of area of 
risk (AAR) and left ventricle (LV) and the ratio of infarct size (IF) and AAR in the WT (n=6) and ATPGD1- Tg 
(n=7) hearts. Results are mean±SEM. *P<0.05 vs WT mice hearts.
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Echocardiographic analysis showed that at baseline mor-
phometric data and function were similar between the 
ATPGD1- Tg and WT mice hearts (Table S1). To determine 
the effect of ATPGD1 overexpression on I/R injury, we 
subjected the WT and ATPGD1- Tg mice hearts to coro-
nary ligation and reperfusion. Quantitative analysis of the 
2,3,5- triphenyl tetrazolium chloride staining showed that 
the AAR was similar between the WT and ATPGD1- Tg 
mice hearts; however, the infarct size decreased signifi-
cantly by ATPGD1 overexpression (Figure 2C through 2E). 
Taken together, these findings suggest that increasing the 
endogenous production of histidyl dipeptides within the 
heart protects from I/R injury.
ATPGD1 Overexpression Improves 
Postischemic Function and Protects 
Myocytes From Hypoxia Reoxygenation 
Injury
Although our results showed that carnosine pro-
tects against I/R in vivo, this could be attributed to 
direct effects of the dipeptide in cardiomyocytes or 
Figure  3. ATPGD1 (carnosine synthase) overexpression prevents contractile dysfunction and 
cardiomyocytes death.
A, Changes in the developed pressure of hearts isolated from the wild- type (WT) and ATPGD1- transgenic 
(Tg) mice during 10 to 12 minutes of perfusion followed by 30 minutes of ischemia and 45 minutes of 
reperfusion. Data are mean±SEM, n=4 mice hearts in each group; *P<0.05 vs WT heart. B and C, Levels 
of lactate dehydrogenase (LDH) and creatine kinase (CK) released in the perfusate collected at different 
intervals of reperfusion. D, LDH release in the WT and ATPGD1- Tg isolated cardiomyocytes under normoxia 
and hypoxia/reoxygenation (H/R) conditions. Results are mean±SEM, n=6 in each group. *P<0.05 vs 
WT normoxia, #P<0.05 vs ATPGD1- Tg normoxia, and ^P<0.05 vs WT H/R- treated cardiomyocytes. LVDP 
indicates left ventricular developed pressures.
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Figure 4. ATPGD1 (carnosine synthase) attenuates aldehyde accumulation and toxicity.
Representative Western blots of the wild- type (WT) and ATPGD1- transgenic (Tg) mice hearts after 30 minutes of sham and coronary 
ligations. The anterior zone (AZ) from sham- operated and the ischemic zone (IZ) from coronary- ligated mice hearts were developed 
with (A) anti–4- hydroxy- trans- 2- nonenal (HNE) and (D) anti- acrolein antibodies and normalized with Amido- black (AB). Relative 
band intensities of HNE (B and C) and acrolein- modified (E and F) protein bands. Data are mean±SEM. ^P<0.05 vs WT sham AZ, 
*P<0.05 vs ATPGD1- Tg AZ, #P<0.05 vs WT IZ; n=4 in each group. G, Representative images of adult cardiomyocytes isolated from 
the WT and ATPGD1- Tg hearts at 0 and 60 minutes of superfusion with HNE (50–60 μmol/L). (Scale bar=100 μmol/L.) H, Survival 
plots of cardiomyocytes isolated from WT (n=7) and ATPGD1- Tg (n=5) hearts superfused with HNE, 100 cells from each heart. 
Data are shown as discrete points, and the curves are best fits of a Weibull survival function. I, Graph showing the mean lifetime 
of WT and ATPGD1- Tg cardiomyocytes in the presence of HNE are presented as mean±SEM. *P<0.05 vs WT HNE superfused 
cardiomyocytes. J, Representative images of myocytes isolated from WT and ATPGD1- Tg hearts at 0 and 60 minutes of superfusion 
with acrolein (5 μmol/L). (Scale bar=100 μmol/L.) K, Survival plots of cardiomyocytes isolated from WT (n=7) and ATPGD1- Tg (n=6) 
hearts superfused with HNE, 100 cells from each heart. Data are shown as discrete points and the curves are best fits of the 
Weibull survival function. L, Graph showing the mean lifetime of WT and ATPGD- Tg cardiomyocytes. *P<0.05 vs WT acrolein- treated 
myocytes.
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neurohormonal and inflammatory responses triggered 
by coronary occlusion and reperfusion. Hence, to ex-
clude neurohormonal and inflammatory responses, we 
perfused isolated WT and ATPGD1- Tg mice hearts in 
the Langendorff mode for 10 to 12 minutes and then 
subjected them to 30 minutes of global ischemia fol-
lowed by 45 minutes of reperfusion. At baseline, the 
left ventricular developed pressures were comparable 
between the WT and ATPGD1- Tg hearts; however, dur-
ing reperfusion, the ATPGD1- Tg hearts had improved 
systolic functional recovery, as demonstrated by higher 
left ventricular developed pressures compared with the 
WT mice hearts (Figure 3A). Similarly, the release of the 
myocardial enzymes lactate dehydrogenase and cre-
atine kinase was less in the ATPGD1- Tg than in the WT 
hearts, indicating the cardiospecific protection attrib-
uted to ATPGD1 overexpression (Figure 3B and 3C).
To localize further the site of action of ATPGD1, we 
isolated the cardiac myocytes from the WT and 
ATPGD1- Tg mice hearts and subjected them to ei-
ther normoxia (5 hours) or hypoxia (3 hours) followed 
by 2  hours of reoxygenation. The WT cardiac myo-
cytes subjected to hypoxia and reoxygenation showed 
greater lactate dehydrogenase release than normoxic 
cardiac myocytes; however, the lactate dehydroge-
nase release in myocytes from the ATPGD1- Tg hearts 
subjected to hypoxia and reoxygenation was similar to 
that from normoxic WT cells, and significantly lower 
than the WT myocytes subjected to hypoxia and reox-
ygenation (Figure 3D). Collectively, these data indicate 
that increased intracellular levels of carnosine protect 
myocytes from the deleterious effects of hypoxia and 
reoxygenation.
ATPGD1 Overexpression Prevents 
Aldehyde Accumulation in Ischemic 
Hearts and Protects Aldehyde Toxicity
Given our findings that ATPGD1- Tg mice hearts are 
protected from I/R injury, we next determined the 
mechanism by which ATPGD1 overexpression affects 
the heart during ischemia. For this, we subjected the 
WT and ATPGD1- Tg mice hearts to 40 minutes of cor-
onary ligation in vivo and analyzed the ischemic zone 
of the ligated hearts and the anterior zone of the sham- 
operated hearts for protein- HNE and protein- acrolein 
adducts by Western blotting. Our results showed that 
the protein- HNE adducts were more abundant in the 
ischemic zone of the WT ischemic hearts than in the 
anterior zone of the sham- operated WT and ATPGD1 
hearts. Importantly, the accumulation of the protein- 
HNE adducts was mitigated in the ischemic zone of 
the ATPGD1- Tg mice hearts (Figure  4A through 4C). 
Moreover, less protein- acrolein adducts accumu-
lated in the ischemic zone of ATPGD1- Tg ischemic 
hearts (Figure 4D through 4F). These observations are 
consistent with the notion that elevated levels of carno-
sine decreases the accumulation of lipid peroxidation–
derived aldehydes in the ischemic hearts.
Given that aldehyde protein- adduct accumulation was 
diminished in the ATPGD1- Tg ischemic hearts, we 
next tested whether ATPGD1 overexpression would 
protect against aldehyde toxicity. Previous work has 
shown that these aldehydes induce myocyte hyper-
contracture.20,21 Therefore, we perfused myocytes iso-
lated from the WT and ATPGD1- Tg hearts with HNE 
for 60  minutes, continuously monitored their shape 
under a light microscope, and calculated cell survival 
using the Weibull distribution function. These analy-
ses showed that although HNE perfusion caused hy-
percontracture in both WT and ATPGD1- Tg cardiac 
myocytes, the mean lifetime of WT myocytes was 
55±2 minutes, whereas the ATPGD- 1- Tg survived with 
a mean lifetime of 72±6  minutes (Figure  4G through 
4I). The ATPGD1- Tg cardiac myocytes were also re-
sistant to acrolein- induced hypercontracture. The 
mean lifetime of WT cardiomyocytes superfused with 
acrolein was 55±2 minutes, which was less than that 
of ATPGD1- Tg myocytes (72±5  minutes; Figure  4J 
through 4L). Collectively, these results suggest that 
high intracellular levels of carnosine protect against 
the toxicity of a structurally diverse range of aldehydes 
generated by lipid peroxidation.
ATPGD1 Overexpression Prevents 
Ischemic Changes in [pH]i and High- 
Energy Phosphate Content
Given that ATPGD1 overexpression enhanced myo-
cardial histidyl dipeptide levels, which can buffer pH,2 
we next tested whether it could also preserve change 
in [pH]i during myocardial I/R. For this, we used 
31P 
NMR spectroscopy to measure the changes in myo-
cardial ATP, phosphocreatine (PCr), and [pH]i during 
I/R. Hearts isolated from the WT and ATPGD1- Tg 
mice were subjected to 20 minutes of perfusion, fol-
lowed by 20  minutes of LFI (10% of baseline) and 
50 minutes of reperfusion. Figure 5A and 5D shows 
the representative 31P NMR spectra at baseline, LFI, 
and reperfusion of the WT and ATPGD1- Tg isolated 
hearts, respectively. From the left to right, the peaks 
present inorganic phosphate; PCr; and γ, α, and β 
phosphates of ATP; and the area under the curve of 
respective resonances were used to calculate the 
amount of each metabolite. The baseline spectra of 
PCr was similar between the WT and ATPGD1- Tg 
hearts, which was reduced to ~50% of baseline in 
both the WT and ATPGD1- Tg hearts during LFI; how-
ever, the decrease was slightly less pronounced in 
the ATPGD1- Tg hearts. During reperfusion, the PCr 
recovery in the WT hearts was nearly 100%; however, 
in the ATPGD1- Tg hearts, the PCr recovery exceeded 
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the baseline levels and remained higher than in WT 
hearts throughout the reperfusion (Figure 5B). Basal 
ATP levels were similar between the WT and the 
ATPGD1- Tg hearts, and LFI resulted in a 40% to 50% 
decrease in ATP levels in the WT hearts, which did 
not recover during reperfusion. In contrast, the ATP 
levels in the ATPGD1- Tg hearts decreased to only 
30% to 40% of the baseline during LFI and remained 
higher than in the WT hearts (Figure 5C). The inor-
ganic phosphate increased substantially in both the 
WT and ATPGD1- Tg hearts during LFI and reached 
preischemic levels during reperfusion in both groups 
(Figure 5E). These results suggest that increasing the 
abundance of carnosine in the heart prevents the 
loss of high- energy phosphates during ischemia and 
promotes their restoration during reperfusion.
At baseline, [pH]i was similar between the WT and 
ATPGD1- Tg hearts (7.13±0.04 versus 7.14±0.01), 
but in WT hearts, [pH]i fell rapidly by 0.34±0.02 pH 
units after 10 minutes and 0.45±0.02 pH units after 
20 minutes of LFI. In contrast, there was less acidosis 
in the ATPGD1- Tg hearts. In these hearts, the mean 
fall of [pH]i was 0.23±0.02 units after 10 minutes and 
0.32±0.03 units after 20 minutes of LFI. During the first 
10 minutes of reperfusion, the [pH]i in the WT hearts 
reached 6.92±0.01 and thus had recovered 0.21±0.01 
pH units. However, in the ATPGD1- Tg hearts, the [pH]i 
reached 7.03±0.01, suggesting a greater recovery 
of [pH]i compared with the WT hearts. The rates of 
[pH]i recovery during 20 to 50 minutes of reperfusion 
was delayed in the WT hearts and did not reach pre-
ischemic levels, whereas the [pH]i in the ATPGD1- Tg 
hearts after 30 to 40 minutes of reperfusion was simi-
lar to baseline (7.08±0.01 versus 7.13±0.01; Figure 5F). 
Taken together, these results provide direct evidence 
that ATPGD1 overexpression augments intracellular 
buffering and mitigates acidosis during I/R. 
Both Buffering and Aldehyde Quenching 
Are Essential for Cardiac Protection by 
Histidyl Dipeptides
Because ATPGD1 overexpression seems to pro-
tect against carbonyl stress and [pH]i imbalance, 
we next examined which of these properties might 
be essential for cardioprotection. To test the rela-
tive contribution of aldehyde quenching and buff-
ering, we synthesized the natural carnosine analog 
anserine, which is methylated at the Nπ residue of 
histidine and has aldehyde- binding capacity similar 
to carnosine (Figure S2).39 However, in comparison 
with carnosine, anserine has a lower buffering ca-
pacity (pKa 7.15).40 In addition, we also synthesized 
balenine, which is methylated at the Nτ residue of 
histidine, and therefore has a higher buffering (pKa 
6.93), yet lower aldehyde binding, capacity than 
does carnosine.21,40 Thus, unlike carnosine, bale-
nine does not protect cardiomyocytes against 
aldehyde- induced hypercontracture.21 To determine 
how the differential biochemical properties of these 
Figure 5. ATPGD1 (carnosine synthase) overexpression enhances buffering capacity during ischemia reperfusion injury.
Representative 31P NMR spectra from wild- type (WT) (A) and ATPGD1- transgenic (Tg) (D) hearts during baseline, low- flow ischemia 
(LFI), and reperfusion. Pi, PCr, γ, α, β denotes inorganic phosphate, phosphocreatine, and resonances of ATP, respectively. Changes 
in PCr (B), ATP (C), Pi (E), and pH (F) during baseline, LFI, and reperfusion. Data are mean±SEM; n=6 mice in each group. *P<0.05 vs 
WT, #P<0.05 vs WT baseline, and ^P<0.05 vs ATPGD- Tg baseline.
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dipeptides influences I/R injury, we perfused iso-
lated C57/BL6 mice  hearts with either anserine or 
balenine (1 mmol/L) and subjected these hearts to 
I/R as previously.  The results of these experiments 
showed that neither balenine nor anserine was able 
to improve the recovery of postischemic contractile 
function (Figure 6A and 6B). The release of cardiac 
enzymes (creatine kinase and lactate dehydroge-
nase) in balenine- perfused and anserine- perfused 
hearts was similar in magnitude to their release in 
untreated WT hearts (Figure  6C through 6F). From 
these results, we infer that the loss of either the buff-
ering capacity or aldehyde binding abolishes the 
cardioprotective effects of histidyl dipeptides, and 
therefore both of these properties are essential for 
the cardioprotective effects of carnosine.
ATPGD1 Overexpression Preserves 
Intermediary Metabolism During Ischemia
Extensive evidence suggests that elevated glucose 
levels could be beneficial to improve recovery from I/R 
Figure 6. Histidyl dipeptide analogs balenine and anserine were unable to restore the contractile 
function.
Changes in the developed pressure of C57BL/6 mice hearts perfused with (A) balenine and (B) anserine 
followed by 30  minutes of ischemia and 45  minutes of reperfusion. Data are mean±SEM; n=4 mice 
hearts in each group. *P<0.5 vs wild- type heart. Levels of creatine kinase (CK) (C and D) and lactate 
dehydrogenase (LDH) (E and F) released in the perfusate collected at different intervals of reperfusion. 
LVDP indicates left ventricular developed pressures.
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injury.41–43 Our results so far suggested that ATPGD1 
overexpression prevents intracellular acidification 
during ischemia. Although it has been proposed that 
carnosine promotes glycolysis by buffering pH,2 di-
rect evidence for such a proglycolytic effect is lacking. 
To examine whether ATPGD1 overexpression affects 
glycolysis, we perfused isolated WT and ATPGD1- Tg 
hearts with13C glucose for 10  minutes followed by 
20 minutes of LFI. Perfusates from these hearts were 
collected at different times and analyzed for13C glu-
cose and13C lactate by liquid chromatography–mass 
spectrometry. We found that the13C glucose levels 
measured at different time points of LFI were similar 
between the WT and ATPGD1- Tg hearts. However,13C 
lactate formation during 1, 2, and 10 minutes of LFI 
was higher in the perfusates of the ATPGD1- Tg rather 
than the WT hearts (Figure  6B and 7A). Taken to-
gether, these results suggest that despite the simi-
lar levels of glucose uptake, ATPGD1 overexpression 
increases glucose use under ischemic conditions, 
presumably by increasing the rates of glycolysis by 
buffering [pH]i.
DISCUSSION
The major findings of this study are that cardiac myo-
cyte–restricted overexpression of ATPGD1 enhances 
myocardial production of carnosine and thereby pro-
tects the heart from I/R injury. In addition, augmenting 
myocardial carnosine levels by β- alanine or carnos-
ine supplementation also imparts cardioprotection. 
Our results show that ATPGD1 overexpression de-
creased the formation of protein- aldehyde adducts 
in the ischemic heart and diminished the toxicity of 
lipid peroxidation products. We also found that the 
overexpression of ATPGD1 attenuated I/R- induced 
changes in [pH]i and intermediary metabolism that ac-
company myocardial I/R. The protective effects of car-
nosine were not duplicated by the structurally related 
histidyl dipeptides anserine and balenine, suggesting 
that the multifunctional chemistry of carnosine is es-
sential for cardioprotection. Taken together, these find-
ings for the first time reveal a direct cardioprotective 
role of ATPGD1 and uncover new aspects of cardiopro-
tection against myocardial ischemic injury targeted by 
ATPGD1- synthesized dipeptides. Given that ATPGD1 
synthesizes multifaceted dipeptides, which are readily 
hydrolyzed in human serum diminishing its bioavailabil-
ity, these results suggest that modulating the endog-
enous production via ATPGD1 overexpression may be 
a key strategy to prevent and attenuate myocardial I/R 
injury and related pathological conditions in humans.
Carnosine, anserine, and balenine are evolutionarily 
conserved dipeptides that are present in a high abun-
dance in energetically active tissues such as the stri-
ated muscles and neurons.2 Among these dipeptides, 
carnosine is widely present in the humans, whereas 
anserine and balenine are mostly found at relatively 
higher levels in birds and whales, respectively.40 In this 
study, we found that the mouse heart contains 300 to 
350 nmoles/g protein of carnosine and 75 to 80 nmo-
les/g protein of anserine, which are consistent with the 
expected distribution of these peptides in mammalian 
hearts. Nevertheless, despite their near ubiquitous 
distribution, the physiological role of these peptides 
is understudied, and it is unclear what specific func-
tion they perform in different tissues. Most previous 
studies on histidyl dipeptides has focused on their 
potential ability to increase exercise capacity, and β- 
alanine is frequently ingested by professional athletes 
Figure 7. Anaerobic glycolysis is increased in carnosine synthase- transgenic (Tg) ischemic hearts.
A, Wild- type (WT) and ATPGD1- Tg isolated hearts were perfused for 10 minutes with 13C D- glucose in the Langendorff mode, followed 
by 20 minutes of low flow ischemia. Levels of (A) 13C D- glucose and (B) 13C- lactate in perfusates collected at different time intervals. 
Data are mean±SEM; n=5 mice in each group. *P<0.05 vs WT heart. ATPGD1 indicates carnosine synthase.
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as a performance- enhancing supplement. The skele-
tal muscle levels of carnosine are increased by high- 
intensity exercise, suggesting that it plays an important 
role in skeletal muscle physiology.36 Although the spe-
cific mechanisms by which carnosine increases exer-
cise capacity remain unknown. It is widely believed that 
it can enhance exercise performance by buffering [pH]i 
and thereby preserve glycolysis during hypoxia36,44,45; 
however, direct evidence regarding the proglycolytic 
effects is lacking. 
In addition to buffering pH, carnosine can also react 
with a variety of electrophiles, such as the reactive al-
dehydes generated by lipid peroxidation. Indeed, in our 
previous work we found that carnosine reacts directly 
with HNE and acrolein and that the resultant conju-
gates are metabolized and excreted in mouse and 
human urine.27 Therefore, carnosine may be an en-
dogenous antioxidant that removes reactive aldehyde 
species, acting in parallel to glutathione- linked detoxi-
fication. This notion is supported by our recent obser-
vation that an increase in carnosine levels attributed to 
β- alanine supplementation results in increased scav-
enging of lipid peroxidation products in human skele-
tal muscle, generated during high- intensity exercise.36 
Carnosine treatment has also been reported to protect 
the brain from ischemic damage,29 and topical admin-
istration of carnosine accelerates wound healing in db/
db mice.46 Carnosine perfusion in isolated hearts has 
also been shown to marginally improve functional re-
covery of isolated ischemic rat and mice hearts.27,28,47 
Nonetheless, the mechanisms underlying the cardio-
protective effects of carnosine remain unknown, and 
it is unclear whether carnosine protects by targeting 
extracellular sites or intracellular pathology and which 
cell types in the heart are targeted. Therefore, we 
generated ATPGD1- Tg mice to selectively increase 
carnosine levels within cardiomyocytes, and we under-
took a comprehensive evaluation of the mechanisms 
of carnosine- mediated cardioprotection. 
We found that the cardiospecific overexpression 
of ATPGD1 reduced the infarct size both in vivo and 
ex vivo and that cardiac myocytes overexpressing 
ATPDGD1 were resistant to hypoxia reoxygenation in-
jury. Although cardiospecific ATPGD1 overexpression 
enhanced the myocardial levels of histidyl dipeptides 
40- to 50- fold and mice fed with β- alanine and car-
nosine enhanced the myocardial carnosine levels 4- to 
7- fold, both treatments had similar infarct- sparing ef-
fects, suggesting that physiological dosing of β- alanine 
and carnosine could be cardioprotective. Together 
these observations provide unequivocal evidence that 
carnosine protects the heart by targeting sites and 
events within cardiac myocytes, without directly af-
fecting extracellular events, neurohormonal changes, 
or even inflammatory responses that accompany myo-
cardial I/R.
Previous work has shown that myocardial ischemia 
is associated with acidification and a decrease in ATP 
levels attributed to the progressive failure of glucose 
and fatty acid metabolism. Myocardial ischemia also 
creates conditions that promote ROS generation, 
which exacerbates tissue injury and induces cell death. 
However, the relationship between acidification and 
loss of ATP is unclear, and the contribution of these 
changes to the ROS generation has not been clarified. 
Moreover, it is unclear to which extent ROS themselves 
or the secondary products they generate mediate tis-
sue injury. Although free radicals and ROS are highly 
reactive, they are short lived and therefore much of 
their injury has been attributed to their secondary, more 
stable, products, such as the aldehydes generated by 
lipid peroxidation.48,49 Several studies have shown that 
lipid peroxidation–derived aldehydes accumulate in 
cardiac tissue within 5 to 10 minutes of ischemia and 
that these aldehydes propagate the I/R injury.16,22,50 Of 
the several reactive aldehydes generated during I/R, 
HNE and acrolein are the most potent and toxic spe-
cies that promote ischemic injury.51–53 Given the ex-
tensive evidence linking reactive aldehydes to tissue 
injury, we investigated whether increasing myocyte lev-
els of carnosine protects the heart by detoxifying lipid 
peroxidation products. We found that ATPGD1 overex-
pression decreased the accumulation of protein- HNE 
and protein- acrolein adducts in the heart and that my-
ocytes isolated from the ATPGD1- Tg heart were resis-
tant to HNE and acrolein- induced hypercontracture. 
When taken together, these observations support the 
notion that the cardioprotective effects of high car-
nosine levels may be related to a greater antioxidant 
capacity of myocytes, specifically their greater ability to 
detoxify the toxic products of lipid peroxidation.
In addition to preventing oxidative injury, carnosine 
could also protect the heart by buffering changes in 
[pH]i. Because of its histidyl group, carnosine is an ef-
ficient buffer with a pKa value near [pH]i.
40 Previous 
studies with racehorses and greyhound dogs as well 
as elite human sprinters have shown that high levels of 
histidyl dipeptides can increase the intracellular buff-
ering capacity of skeletal muscle.54,55 Moreover, it has 
been recently suggested that the buffering potential of 
the heart, augmented by exercise, might be associated 
with an increase in the cardiac pool of histidyl dipep-
tides.56,57 Changes in [pH]i are an important aspect 
of I/R injury. Extensive data have shown that acidifi-
cation during I/R promotes cardiac injury by affecting 
cardiac metabolism and mechanics.58–60 Because 
carnosine has been shown to act as a mobile buffer 
that regulates the Ca2+ and H+ signaling in isolated 
cardiac myocytes,61 it seems that intracellular buffer-
ing may be important aspect of its cardioprotective 
properties. Indeed, we found that although ATPGD1 
overexpression did not affect basal [pH]i, it prevented 
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the steep fall in pH and decreased the perpetuation of 
acidotic pH during reperfusion. These results showing 
that ATPGD1 overexpression diminishes the decline in 
[pH]i provides direct evidence that [pH]i buffering by 
histidyl dipeptides may be an essential feature of the 
cardioprotective effects of carnosine. Nevertheless, 
pH buffering does not seem to be the sole mechanism 
of protection because perfusion with balenine, which 
is as efficient a buffer as carnosine, did not ameliorate 
I/R injury, suggesting that simply buffering [pH]i during 
I/R is not sufficient for limiting I/R and that properties of 
carnosine, other than buffering [pH]i, may be pertinent 
to its cardioprotective effects. Nonetheless, the lack of 
protection by anserine, which has a lower buffering ca-
pacity than carnosine, suggests that pH buffering by 
carnosine is important. Because anserine has a lower 
buffering capacity, we suggest that both aldehyde 
quenching and buffering intracellular pH are import-
ant components of carnosine- mediated protection. 
Therefore, in comparison with previous interventions 
with buffers and antioxidants, carnosine has a more 
superior protective profile. Based on this evidence, it 
appears that buffering and aldehyde quenching prop-
erties of carnosine, optimized by natural selection, may 
be ideally suited for the protection of ischemic tissue. 
This property of carnosine seems to be in contrast to 
anserine and balenine, which are mostly abundant 
in avian and whale hearts,40 suggesting that greater 
abundance of carnosine may be acquired by land 
mammals to optimize both the buffering and aldehyde- 
quenching properties of histidyl dipeptides. 
Our findings further suggest that the mechanism link-
ing the cardioprotective effects of carnosine may relate to 
the prevention of acidification and quenching of reactive 
aldehydes generated during I/R injury. These changes 
are likely to prevent metabolic derangements in isch-
emic tissue. Indeed, previous work has shown that inter-
ventions that promote glucose supply and use protect 
the heart during ischemia and improve recovery during 
reperfusion.43,62–64 Clinical studies with glucose- insulin- 
potassium therapy, which augments glucose metab-
olism during acute myocardial ischemia, improves the 
outcome in patients receiving thrombolytic therapy.65,66 
In addition, the protective effects of buffering [pH]i may 
also be related to the preservation of energy metabo-
lism. For instance, it has been reported that during isch-
emia, delaying [pH]i decline by proton- buffering agents 
preserves glycolysis and prevents myocardial injury.67,68 
Our experiments with ATPGD1 hearts provide a direct 
link between the two phenomena. We found that al-
though glucose uptake in the WT and ATPGD1- Tg mice 
hearts was similar, lactate formation was increased, 
suggesting that increasing the buffering capacity during 
ischemia facilitates anaerobic glycolysis. That ATPGD1 
hearts also showed less severe depletion of high- energy 
phosphates further reinforces the view that myocardial 
energetics could be preserved during ischemia by buff-
ering [pH]i. Whether the salutary effects of ATPGD1 
expression on glycolysis are attributed to buffering, al-
dehyde quenching, or direct effects on metabolic path-
ways requires further investigation. Nevertheless, our 
current data provide strong evidence that carnosine pre-
vents oxidative stress, acidification, and metabolic de-
rangements that are key features of myocardial I/R injury 
and therefore have high clinical relevance. Because car-
nosine is an endogenous dipeptide and its myocardial 
levels could be modulated by exogenous supplementa-
tion or by modulation of the endogenous production, it 
could be used therapeutically to promote recovery from 
myocardial injury or prophylactically to prevent myocar-
dial injury in susceptible individuals.
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Data S1. 
 
SUPPLEMENTAL MATERIALS AND METHODS 
 
Enhance histidyl dipeptide levels within the cardiac tissue  
-Alanine and carnosine feeding. To enhance histidyl dipeptide pool within cardiac tissue, we treated WT 
C57BL/6 mice (12-14 week) with -alanine (20 g/L) or carnosine (10 g/L) in drinking water or water alone for 
seven days. Heart and skeletal muscle from the treated and untreated mice were collected and analyzed for 
different histidyl dipeptides levels using LC/MS.  
Generation of cardio specific carnosine synthase (ATPGD1) transgenic mice. To enhance endogenous 
production of histidyl dipeptides within cardiac tissue, we generated cardio specific ATPGD1 transgenic (Tg) 
mice. Full protein-coding sequence of the mouse (m) ATPGD1 cDNA (2.84 kb a kind gift from Dr. Emile Van 
Schaftingen, Ludwig Institute for Cancer Research, Universite Catholique de Louvain, Belgium) was cloned 
under the control of mouse alpha-myosin heavy chain promoter (-MHC; 5.5 kb), 0.6 Kb HGH (human growth 
hormone) poly A was ligated at the 3’ end of the minigene construct.  Nucleotide sequencing and comparisons 
with published sequences verified the construct as mATPGD1 cDNA. The resultant transgene (9.04 Kb) 
composed of -MHC promoter, the entire protein-coding region of ATPGD1 and HGH polyadenylation signal 
sequence. The transgene construct was linearized, purified, and microinjected into the pronuclei of fertilized 
ova to generate -MHC-ATPGD1-Tg mice at the University of Cincinnati, Cincinnati, OH Transgenic Core. Four 
transgenic founders with the varying copy number of the transgene were generated on the C57Bl/6 background. 
Founder mice were identified by genomic PCR using the following primers: Forward-5’- AGT CCT GGT GGG 
AGA GCC ATA -3’ and Reverse 5’ – GCC AAG CAG GGG ACA GGC AAA -3’ corresponding to -MHC 5’UTR 
and the ATPGD1 coding region, respectively. Two transgenic (TG) lines were established and distinguished 
from their non-transgenic wild type littermates (WT) cohorts by PCR. 
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Myocardial ischemia and reperfusion (I/R) injury in-vivo and assessment of area at risk and infarct size. 
The I/R injury was produced by subjecting mice to a 30 min of coronary occlusion followed by 24 h of reperfusion 
as described previously69-71. Briefly, the mice (10-14 weeks of age) were anesthetized with pentobarbital 
sodium (50mg/kg, i.p) intubated and ventilated at room air supplemented with oxygen. The body temperature 
was monitored with a rectal probe and maintained at 370.2C with a heating pad. To replace blood loss, blood 
from a donor mouse was given intravenously. The chest was opened through a midline sternotomy, and a 
nontraumatic balloon occluder was applied on the left anterior descending coronary artery 2-3 mm from the tip 
of left auricle. Successful performance of the surgery was verified by noting the development of a pale color in 
the distal myocardium on inflation of the balloon and return of a bright red color due to hyperemia after deflation 
and by observing the ST-segment elevation and widening of the QRS complex on the ECG during ischemia 
and their resolution after reperfusion. Following the coronary occlusion/reperfusion, the chest was closed in 
layers, and the mice were allowed to recover under close monitoring. Heart was excised and perfused with 
Krebs-Henseleit (KH) solution through an aortic cannula. To determine the area of infarcted myocardium from 
the viable myocardium, the heart was perfused with 1% triphenyl tetrazolium chloride in phosphate buffer. To 
delineate the area of occlusion, the coronary artery was tied at the site of previous occlusion, and the aortic 
root was perfused with 10% Pthalo blue dye. The region of risk was identified by the absence of blue dye, 
whereas the rest of left ventricle was stained dark blue. The left ventricle was cut into transverse slices, which 
were fixed in 10% neutral buffered formaldehyde, weighed, and photographed under a microscope. The 
corresponding areas were measured by computerized planimetry and from these measurements; the infarct 
size was calculated as the percentage of region at risk. 
In the second set of experiments, coronary ligation was performed, to analyze the formation of aldehyde protein 
adduct during ischemic injury. Hearts from the WT and ATPGD1-Tg mice were collected following 40 min of 
ligation. The ischemic zone of ligated mice and the anterior zone of sham-operated mice were clamp frozen 
and analyzed by Western blotting.  
Langendorff perfusion 
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Global ischemia-reperfusion (I/R) ex vivo. To exclude the neurohormonal effects associated with in-vivo 
model of I/R, we performed I/R in a Langendorff mode as described previously27. Mice were anesthetized 
(sodium pentobarbital, 60mg/kg body weight, heparin, 10 units/g body weight), the thorax of mice was opened 
and the hearts were removed, placed immediately in the ice-cold KH buffer; mM 118 NaCl, 4.7 KCl, MgCl2, 
CaCl2, KH2PO4, NaHCO3 and 11 glucose. The buffer was heated at 37C and continuously gassed (95% O2, 
5%CO2). Hearts from the WT and ATPGD1-Tg, mice were continuously perfused at a constant pressure of 80 
mmHg in the Langendorff mode and after 20-30 min of perfusion, the isolated hearts were subjected to 30 min 
of ischemia followed by 45 min of reperfusion. Functional recovery of the hearts was measured by placing a 
food grade plastic wrap, fluid-filled balloon to a pressure of 5-8 mm Hg. Left ventricular pressure was recorded 
using an APT300 pressure transducer (Harvard Apparatus, Holliston, MA) connected to a ML221 bridge 
amplifier, a Power lab 16/30 A/D board, and a PC running Lab Chart Pro v7 (AD Instruments, Colorado Springs, 
CO). Perfusion flow rate was monitored using a 1PXN inline probe and TS410 flowmeter (transonic Systems 
Inc., Ithaca, NY) and was typically between 1.5 and 2 mL/min. Left ventricular developed pressure was derived 
from the pressure trace as the difference between systolic and diastolic pressures. Perfusates were collected 
on ice and the levels of creatinine kinase (CK) and lactate dehydrogenase (LDH) were measured using kits 
purchased from Thermo-Electron.  
In a second line of experiments, we tested which dipeptide analogue could lead to recovery of function following 
ischemia. For these experiments, wild type (WT) C57/Bl6 mice (12-14 weeks old) were perfused with either 
balenine and anserine (1mM), followed by 30 min of ischemia and 45 min of reperfusion and the recovery of 
cardiac function was monitored in a Langendorff mode as described above.  
Low flow ischemia and 13C D-glucose perfusion: To determine whether ATPGD1 overexpression influences 
the glycolytic fluxes during ischemic injury, isolated WT and ATPGD1-Tg mice hearts were perfused in the 
Langendorff mode for 10 min in a KH buffer; mM 118 NaCl, 4.7 KCl, MgCl2, CaCl2, KH2PO4, NaHCO3 and 11 
13C-D-glucose followed by 15 min of low flow ischemia (LFI, 10% of baseline). The effluent was collected at 
regular intervals and analyzed for 13C D-glucose and 13C lactate.  
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31P Nuclear Magnetic Resonance Spectroscopy: Hearts isolated from the WT and ATPGD1-Tg mice were 
perfused in a Langendorff mode with KH buffer at constant coronary pressure of 75 mmHg at 37C for 10 min 
followed by 20 min LFI (10% of baseline) and 50 min reperfusion.  31P-NMR spectra were collected continuously 
and simultaneously during measurement of isovolumic contractile performance using 31P-NMR spectroscopy. 
72  Isolated perfused hearts and an external standard containing 4.51 mol of phenylphosphonic acid (PPA) in 
a small sealed plastic tube were placed in a 10-mm glass NMR sample tube and inserted into a 10 mm Varian 
broad band probe situated in an 89-mm bore 9.4-T superconducting magnet. To improve homogeneity of the 
NMR-sensitive volume, the perfusate level was adjusted so that the heart was submerged in buffer. 31P-NMR 
spectra were obtained using 60 pulses and a recycle time of 2.4 S, 6,000-Hz sweep width and 2 K data points 
at 161.94 MHz using a Varian Inova spectrometer (Varian Inc., Palo Alto, CA).  Single spectra were collected 
during 10 min periods and consisted of data averaged from 256 free induction decays. Spectra were processed 
using 20-Hz exponential multiplication and zero and first-order phase corrections. The resonance areas of 
phosphocreatine (PCr), ATP, inorganic phosphate (Pi) and the chemical shifts of Pi were quantified using 
Bayesian Analysis Software (G.L. Bretthorst Washington University, St. Louis, MO) 73.  By comparing the 
amplitude under the peaks from fully relaxed (recycle time 15 sec) and those of partially saturated (recycle time 
2.4 sec) spectra, the correction factors for saturation were calculated for ATP (1.041), PCr (1.285), Pi (1.157) 
and PPA (1.283). 
 
Cell culture studies  
Isolation of adult cardiomyocytes. Cardiac myocytes from the WT and  ATPGD1-Tg mice hearts (age 12-16 
weeks) were isolated using  Langendorff perfusion as described previously.74 21 Isolated hearts from these mice 
were rinsed in physiological saline and perfused with oxygenated (95% O2- 5%CO2), Ca2+- free modified Tyrode 
bicarbonate buffer (buffer A mM: NaCl 126, KCL 4.4, MgCl2 1.0, NaHCO3 18, glucose 11, HEPES 4, 2,3 
butanedione monoxime 10, taurine 30, pH 7.35) at 37C for 5 min. The extracellular matrix was digested by 
buffer containing buffer A with Liberase Blendzyme type I 0.25 mg/mL, 1mg/mL albumin, 0.015 mg/mL DNase, 
0.015 mg/mL proteinase in the 50 mL of recirculating digestion buffer (buffer A with 25 M CaCl2) for 12-15 
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min. Hearts were separated in mincing buffer (10 mL digestion buffer with 9 mg/mL albumin and Liberase) and 
cells were allowed to settle. CaCl2 was reintroduced in a graded fashion at 5- min intervals (five total steps) to 
sequentially increase the Ca2+ concentration to 500 M. 
Hypoxia reoxygenation of adult cardiomyocytes. Cardiomyocytes isolated from  WT and ATPGD1-TG mice 
hearts were subjected to 2-3 h of hypoxia using a controlled hypoxic chamber (Billups-Rothenberg Modulao, 
Incubator Chamber) maintained at 37C. Freshly isolated cells were maintained in serum free/ glucose free 
HEPES-buffered medium (mM: NaCl 113, KCL 4.7, HEPES 10, MgSO4 1.2, taurine 30, CaCl2 1, pH 6.2 ) at 
37C. Cells were allowed to settle down, supernatant was removed and replaced with hypoxia buffer (glucose 
free/serum free HEPES buffered medium that was bubbled with nitrogen (N2). The dishes were filled with 1 mL 
of hypoxia buffer and incubated in a humidified hypoxic chamber containing: 1% O2, 5% CO2 and 94% N2 at 
37C. Following hypoxia, the cells were re oxygenated with 1 mL of HEPES buffered medium supplemented 
with serum (10%) and glucose (11 mM) bubbled with O2 and placed under normoxic conditions. For control 
conditions, freshly isolated cells were washed twice with a HEPES-buffered medium supplemented with serum 
(5%) and glucose (5.5 mM) and placed under normoxic conditions. Reoxygenation was mimicked by adding 1 
mL of the medium. The supernatant was collected and analyzed for LDH release. 
Superfusion of isolated cardiomyocytes with HNE and acrolein. To examine whether the increase in 
endogenous production of histidyl dipeptides protects against aldehyde induced hypercontracture, adult 
cardiomyocytes from the WT and ATPGD1-Tg mice hearts were superfused with 50-60 M HNE or 5 M 
acrolein for 60 min as described previously.21 Digital images of approx. 100 cardiomyocyte/field were acquired 
at 5 min interval to quantify the number of hypercontracted and non-hypercontracted cells following aldehyde 
treatment.  
Western blot analysis 
 The anterior zone of sham operated and ischemic zone of the ligated mice hearts were homogenized and 
separated by SDS-PAGE. Tissues were homogenized in RIPA buffer (20mM Tris-HCl pH7.5, 150 mM NaCl, 
1mM EDTA, 1mM EDTA, 1mMEGTA, 1% NP-40) and separated by SDS-PAGE. Immunoblots were developed 
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using anti-acrolein (0.25 g/ mL, Novus Biological), anti-HNE (0.5 g/mL, Abcam) and anti- ATPGD1 (0.25 g/ 
mL COSMO Bio Company) antibodies. Western blots were developed using ECL Plus reagent and detected 
with a Typhoon 9400 Variable mode imager. Band intensity was quantified by using an Image Quant TL 
software and bands were normalized to amido black or tubulin.  
LC/MS studies 
Measurement of histidyl dipeptides by LC/MS. Histidyl dipeptides in the heart and skeletal muscle were 
measured by LC/MS as described previously36. Briefly the isolated tissues from mice were homogenized in 
extraction buffer containing 10 mM HCl and 200 M tyrosine-histidine as an internal standard (IS). 
Homogenates were sonicated on ice for 10 s, centrifuged at 16,000  g for 10 min at 4C. Supernatants were 
injected into TQ-S micro mass spectrometer in positive mode, the samples were diluted in 75% acetonitrile/25% 
water. The dipeptides were separated and identified by using Water ACQUITY UPLV H-Class system coupled 
with a Xevo TQ-S micro triple quadrupole mass spectrometer (MS). The analytes were separated by a Waters 
Acquity BEH HILIC column (1.7m, 2.1 50) equipped with an in-line frit filter unit. The analytes were eluted by 
using a binary solvent system consisting of 10 mM ammonium formate, 0.125% formic acid in 50% 
acetonitrile/50% water for mobile phase A and 10 mM ammonium formate 0.125% formic acid in 95% 
acetonitrile/5% water for mobile phase B at a flow rated of 0.55 ml/min. Initial conditions were 0.1:99.9 A/B 
ramping to 99.9:0.1 A/B over 5 min then quickly ramping to 0.1:99.9 A/B over 0.5 min. This initial composition 
was held from 5.5 to 8 min to equilibrate the column for the next injection. Dipeptides were quantified using the 
LC/MS calibration curve of relative area of carnosine and anserine to internal standard tyrosine-histidine and 
expressed as mole/mg wet wt. or mole/mg protein. For carnosine m/z 227→110, anserine m/z 241→110, and 
tyrosine-histidine m/z 319→110, Da MRM transitions were followed.    
13C glucose and 13C lactate analysis.  
Perfusates collected from the WT and ATPGD1-Tg hearts perfused with 13C glucose and subjected to low 
flow ischemia as described above were dried and dissolved in 200 µL 20% acetonitrile and vigorously vortex-
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mixed for 3 min. After centrifugation at 14,000 rpm, 4 oC for 20 min, the supernatant was collected for 2DLC-
MS/MS analysis.  
All samples were analyzed on a Thermo Q Exactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer 
coupled with a Thermo DIONEX UltiMate 3000 HPLC system (Thermo Fisher Scientific, Waltham, MA, USA). 
The UltiMate 3000 HPLC system was equipped with a reverse phase chromatography (RPC) column and a 
hydrophilic interaction chromatography (HILIC) column. The RPC column was an ACQUITY UPLC HSS T3 
column (150 × 2.1 mm i.d., 1.8 µm) purchased from Waters (Milford, MA, USA). The HILIC column was a 
SeQuant® ZIC®-cHILIC HPLC column (150 × 2.1 mm i.d., 3 µm) purchased from Phenomenex (Torrance, CA, 
USA). The two columns were configured in parallel 2DLC mode 75. For 2DLC separation, H2O with 0.1% formic 
acid was used as the mobile phase A for RPC and 10 mM ammonium acetate (pH 3.25) was used as the 
mobile phase A for HILIC. Acetonitrile with 0.1% formic acid was used as mobile phase B for both RPC and 
HILIC. The RPC gradient was as follows: 0 min, 5% B, hold for 5.0 min; 5.0 min to 6.1 min, 5% B to 15% B; 6.1 
min to 10.0 min, 15% B to 60% B, hold for 2.0 min; 12.0 min to 14.0 min, 60% B to 100% B, hold for 13.0 min; 
27.0 min to 27.1 min, 100% B to 5% B, hold for 12.9 min. The gradient for HILIC separation was: 0 to 5.0 min, 
95% B to 35% B, hold for 1.0 min; 6.0 min to 6.1 min, 35% B to 5% B, hold for 16.9 min; 23.0 min to 23.1 min, 
5% B to 95% B, hold for 16.9 min. The flow rate was 0.4 mL/min for RPC and 0.3 mL/min for HILIC. The column 
temperature was 40 °C for both columns. The injection volume was 2 µL for each column. 
To avoid systemic bias, the samples were analyzed by 2DLC-MS in a random order. All samples were first 
analyzed by 2DLC-MS positive mode followed by 2DLC-MS negative mode, to obtain the full MS data of each 
metabolite. For quality control purpose, a group-based pooled sample was prepared by mixing a small portion 
of the supernatant from all unlabeled samples in one group. One pooled sample was analyzed by 2DLC-MS 
after injection of every 5 biological samples. All pooled samples were analyzed by 2DLC-MS/MS in positive 
and negative mode respectively to acquire MS/MS spectra of each metabolite at three collision energies (20 
eV, 40 eV and 60 eV). 
MetSign software was used for spectrum deconvolution, metabolite identification, cross-sample peak list 
alignment, normalization, and statistical analysis 76-78. To identify metabolites, the 2DLC-MS/MS data of the 
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pooled samples were first matched to an in-house MS/MS database that contains the parent ion m/z, MS/MS 
spectra, and retention time of 205 metabolite standards. The thresholds used for metabolite identification were 
MS/MS spectral similarity ≥ 0.4, retention time difference ≤ 0.15 min, and m/z difference ≤ 4 ppm. The 2DLC-
MS/MS data without a match in the in-house database were then analyzed using Compound Discoverer 
software (v2.0, Thermo Fisher Scientific, Inc., Germany), where the threshold of MS/MS spectrum similarity 
score was set as ≥ 40 with a maximum score of 100. The remaining peaks that did not have a match were then 
matched to the metabolites in -house MS/MS database using the parent ion m/z and retention time to identify 
metabolites that do not have MS/MS spectra. The thresholds for assignment were parent ion m/z ≤ 4 ppm and 
retention time difference ≤ 0.15 min. 
Synthesis of histidyl dipeptide analogues anserine and balenine  
(a) Balenine was synthesized as mentioned previously.21 
(b) Anserine synthesis 
(S)-Methyl 3-(1H-imidazol-5-yl)-2-(2,2,2-trifluoroacetamido) propanoate (3):  
 
To L-histidine dihydrochloride (5.00 g, 20.65 mmol) in methanol (100 mL), we added ethyl 2,2,2-
trifluoroacetate (2.70 mL, 22.72 mmol) and triethyl amine (1.52 mL, 82.6 mmol) and the reaction 
mixture was stirred for 5 h at room temperature (RT). The solvent was evaporated to dryness and the 
obtained solid was purified by silica gel chromatography to get the desired product, (S)-methyl 3-(1H-
imidazol-5-yl)-2-(2,2,2-trifluoroacetamido) propanoate, (3, 4.10 g, 75% yield) as an off-white solid 
compound. 
1H NMR (D2O, 400 MHz): δ 7.60 (s, 1H), 6.87 (s, 1H), 4.76 – 4.67 (m, 1H), 3.66 (s, 3H), 3.17 – 2.96 
(m, 2H) ppm. 
(S)-Methyl 2-(2,2,2-trifluoroacetamido)-3-(1-trityl-1H-imidazol-4-yl) propanoate (4):  
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Trityl chloride (5.60 g, 20.36 mmol) and triethyl amine (8.53 mL, 61.53 mmol) were dissolved in 
anhydrous benzene (100mL) and (S)-methyl3-(1H-imidazol-5-yl)-2-(2,2,2-trifluoroacetamido) 
propanoate (3, 5.40 g, 20.36 mmol) was added. The resulting reaction mixture was refluxed for 1 h 
and the solvent was evaporated. Obtained semi pure compound was purified with silica gel column 
using dichloromethane and methanol was used as eluents to get (S)-methyl 2-(2,2,2-
trifluoroacetamido)-3-(1-trityl-1H-imidazol-4-yl) propanoate (4, 5.80 g, 55% yield) as an off-white solid 
compound. 
1H NMR (CDCl3, 400 MHz): δ 8.89 – 8.87 (d, 1H), 7.40 (s, 1H), 7.37 – 7.30 (m, 9H), 7.13 – 7.07 (m, 
6H), 6.57 (s, 1H), 4.85 – 4.79 (m, 1H), 3.63 (s, 3H), 3.16 – 3.11 (m, 1H), 3.06 – 3.00 (m, 1H) ppm. 
(S)-4-(3-Methoxy-3-oxo-2-(2,2,2-trifluoroacetamido) propyl)-3-methyl-1-trityl-1H-imidazol-3-ium 
iodide (5):  
 
(S)-Methyl 2-(2,2,2-trifluoroacetamido)-3-(1-trityl-1H-imidazol-4-yl) propanoate (3.50 g, 6.90 mmol) 
was dissolved in anhydrous acetonitrile (100 mL) and methyl iodide (0.86 mL, 13.80 mmol) was 
added. The resulting reaction mixture was refluxed for 1 h and the solvent was evaporated. Obtained 
crude was purified with silica gel column using dichloromethane and methanol as eluents to get (S)-
4-(3-methoxy-3-oxo-2-(2,2,2-trifluoroacetamido) propyl)-3-methyl-1-trityl-1H-imidazol-3-ium iodide (5, 
4.0 g, 89% yield) as a yellow solid compound. 
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1H NMR (CDCl3, 400 MHz): δ 8.26 – 8.25 (d, 1H), 7.48 – 7.38 (m, 7H), 7.35 – 7.20 (m, 10H), 4.86 - 
4.79 (m, 1H), 4.03 (s, 3H), 3.78 (s, 3H), 3.56 – 3.41 (m, 2H) ppm.  
 (S)-1-Carboxy-2-(1-methyl-1H-imidazol-5-yl)ethanaminium chloride (6):  
 
In a round bottom flask, we added (S)-4-(3-methoxy-3-oxo-2-(2,2,2-trifluoroacetamido) propyl)-3-
methyl-1-trityl-1H-imidazol-3-ium iodide (5, 4.0 g, 6.16 mmol) and 4N HCl (100 mL). The reaction 
mixture was refluxed for 6 h, and evaporated to dryness, and the solid obtained was washed with 
hexanes and dried to get (S)-1-carboxy-2-(1-methyl-1H-imidazol-5-yl) ethanaminium chloride, (6, 1.10 
g, 87% yield) as a yellow solid compound. 
1H NMR (D2O, 400 MHz): δ 8.62 (s, 1H), 7.36 (s, 1H), 4.26 – 4.19 (m, 1H), 3.78 (s, 3H), 3.41 – 3.25 
(m, 2H) ppm. 
 
 (S)-Methyl 2-amino-3-(1-methyl-1H-imidazol-4-yl) propanoate hydrochloride (7):  
 
In 300 mL of methanolic hydrochloric acid was added (S)-2-amino-3-(1-methyl-1H-imidazol-5-yl) 
propanoic acid hydrochloride (2.60 g, 12.64 mmol) at room temperature. The reaction mixture was 
then refluxed for 48 h, and evaporated to dryness to get (S)-methyl 2-amino-3-(1-methyl-1H-imidazol-
4-yl) propanoate hydrochloride, (7, 2.5 g, 90% yield) as a white solid. (Note: Methanolic-HCl was made 
by purging HCl gas into required methanol for 5 min.) 
1H NMR (D2O, 400 MHz): δ 8.62 (s, 1H), 7.39 (s, 1H), 4.45 – 4.19 (m, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 
3.47 - 3.26 (m, 2H) ppm. 
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(S)-Methyl 2-(3-(tert-butoxycarbonylamino) propanamido)-3-(1-methyl-1H-imidazol-5-yl) 
propanoate (8):  
 
Added sequentially to a reaction flask under nitrogen were (S)-methyl 2-amino-3-(1-methyl-1H-
imidazol-5-yl)propanoate hydrochloride (7, 2.0 g, 9.10 mmol), boc-b-alanine (1.89 g, 10.02 mmol), 
EDC (N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide) (1.92 g, 10.02 mmol) followed by DCM (100 
mL) and then N-methylmorpholine (4.00 mL, 36.4 mmol via syringe). The contents were stirred at 
room temperature under nitrogen and the solids gradually dissolved. The contents were stirred at 
room temperature for 24 h, and then slowly diluted into iced water and extracted with DCM. The 
organic phase was dried evaporated and chromatographed using dichloromethane and methanol as 
eluents to get (S)-methyl 2-(3-(tert-butoxycarbonylamino) propanamido)-3-(1-methyl-1H-imidazol-5-
yl) propanoate (8, 2.0 g, 62% yield) as an off-white solid compound. 
1H NMR (CDCl3, 400 MHz): δ 7.37 (s, 1H), 6.75 (s, 1H), 6.66 – 6.50 (m, 1H), 5.15 – 5.08 (m, 1H), 4.82 
– 4.77 (m, 1H), 3.74 (s, 3H), 3.57 (s, 3H), 3.45 – 3.30 (m, 3H), 3.16 – 3.02 (m, 1H), 2.50 – 2.35 (m, 
2H), 1.42 (s, 9H) ppm. 
 
L-Anserine (9):  
 
To (S)-methyl 2-(3-(tert-butoxycarbonylamino) propanamido)-3-(1-methyl-1H-imidazol-4-yl) 
propanoate (8, 2.2 g, 6.2 mmol) was added 2N NaOH (18.6 mL) in THF (50 mL) and methanol (50 
mL) and the reaction was stirred for the 24 h at RT. Solvent was evaporated and the reaction mixture 
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was neutralized by 1N HCl to pH 3. It was further stirred and neutralized by aqueous saturated sodium 
bicarbonate solution. All the water was evaporated to dryness and the obtained solid was triturated 
with DCM and dried again. The obtained solid was dissolved in hot ethanol and passed through the 
celite plug, twice. Filtrate was evaporated and dried under high vacuum to get the L-anserine (9, 1.30 
g, 87% yield) as a white solid compound.   
1H NMR (D2O, 400 MHz): δ 8.61 (s, 1H), 7.27 (s, 1H), 4.54 – 4.50 (m, 1H), 3.86 (s, 3H), 3.31 – 3.19 
(m, 3H), 3.14 – 3.07 (m, 1H), 2.80 – 2.64 (m, 2H) ppm; 13C NMR (D2O, 100 MHz) δ 176.3, 171.7, 
135.1, 131.3, 117.5, 53.2, 35.2, 33.1, 31.9, 25.8. 
Echocardiographic analysis of cardiac function  
Transthoracic echocardiography of the left ventricle was performed using a Vevo 770 
echocardiography system as described previously. 79 Briefly the body temperature of the mice was 
maintained (36.5 -37.5C) using a rectal thermometer interfaced with a servo-controlled heat lamp. 
Mice were anesthetized with 2% isoflurane, maintained under anesthesia with 1.5% isoflurane. The 
chest was shaved and the mouse was placed chest up on an examination board interfaced with the 
Vevo 770. The 707-B (30 MHZ) scan head was used to obtain 2D images of the parasternal long axis. 
M-modes were taken from the same anatomical position. The probe was then rotated to acquire a 
short axis view of the heart. Stroke volume (SV) was calculated as: Diastolic Volume-Systolic Volume. 
Ejection fraction was calculated as (SV/Diastolic Volume) *100%. Cardiac output was determined by: 
SV*HR. All images were acquired with the Vevo 770’s rail system to maintain probe placement and 
allow for precise adjustments of position. Left ventricular diameters during diastole (LVIDd) and left 
ventricular diameter during systole (LVIDs) and heart rate (HR) were determined from long axis M-
modes. Left ventricular fractional shortening (%FS) was calculated as ((LVIDd-LVIDs)/LVIDd) *100%.  
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Figure S1. Histidyl dipeptide levels are enhanced in the carnosine synthase (ATPGD1-Tg) 
heart.  
 
Levels of carnosine in the (A) heart and (C) gastrocnemius skeletal muscle of WT and ATPGD1-
Tg mice. Levels of anserine in the (B) heart and (D) skeletal muscle of WT and ATPGD1-Tg mice. Levels 
of anserine in the hearts of (E) -alanine and (F) carnosine fed mice. Data is presented as meanSEM, n=4 
mice in each group, *p<0.05 vs WT heart. 
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Figure S2. Synthesis of anserine.  
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Table S1. Echocardiographic parameters of the wild type and ATPGD1-Tg hearts, age 12-14-week, n=7 
in each group.  
 
 
 
 Baseline 
 WT ATPGD1-Tg 
LVIDd(mm) 3.95±0.05 3.98±0.07 
LVIDs(mm) 2.27±0.07 2.48±0.09 
EF(%) 63±1 60±1 
Heart rate 580±5 540±5 
FS 41±1 38±2 
 
 
Data are presented as S.D. in each group. 
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